RxDoctor Payments Data

Conrad Reed, MD

Pulmonary Disease · Abington, PANPI 1760408371

Payments from drug & device makers

$133in general payments, 2019–2025

Across 7 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$37
  • Merck$25
  • Inspire Medical Systems, Inc.$24
  • United Therapeutics Corporation$18
  • Harmony Biosciences LLC$17
  • AstraZeneca$12

What the payments were for

  • Food & beverage$10378%
  • Education$3022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$133 in reported general payments places this provider in the 20th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$173,852
Medicare patients
521
Services billed
1,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter177$169,012
AdempasRiociguat12$162,687
Breo ElliptaFluticasone/Vilanterol215$133,440
Incruse ElliptaUmeclidinium Bromide98$49,000
Spiriva RespimatTiotropium Bromide50$40,930
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr55$40,246
Ambrisentan12$34,200
Arnuity ElliptaFluticasone Furoate37$20,315
Spiriva HandihalerTiotropium Bromide20$13,857
SymbicortBudesonide/Formoterol Fumarate23$9,146
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$8,482
Albuterol Sulfate HfaAlbuterol Sulfate199$5,837
Advair DiskusFluticasone Propion/Salmeterol11$4,832
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,884
Wixela InhubFluticasone Propion/Salmeterol20$3,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$37$412,013582 claims
AstraZenecaSymbicort$12$9,14623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →